- Home
- VVV vs TGTX Comparison
VVV vs TGTX Comparison
Compare VVV & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- TGTX
- Stock Information
- Founded
- VVV 1866
- TGTX 1993
- Country
- VVV United States
- TGTX United States
- Employees
- VVV N/A
- TGTX N/A
- Industry
- VVV Major Chemicals
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- TGTX Health Care
- Exchange
- VVV Nasdaq
- TGTX Nasdaq
- Market Cap
- VVV 5.0B
- TGTX 4.2B
- IPO Year
- VVV 2016
- TGTX 1995
- Fundamental
- Price
- VVV $40.67
- TGTX $31.99
- Analyst Decision
- VVV Buy
- TGTX Strong Buy
- Analyst Count
- VVV 12
- TGTX 4
- Target Price
- VVV $43.00
- TGTX $42.50
- AVG Volume (30 Days)
- VVV 1.4M
- TGTX 2.0M
- Earning Date
- VVV 08-06-2025
- TGTX 11-03-2025
- Dividend Yield
- VVV N/A
- TGTX N/A
- EPS Growth
- VVV 68.45
- TGTX N/A
- EPS
- VVV 2.14
- TGTX 0.36
- Revenue
- VVV $1,692,000,000.00
- TGTX $454,069,000.00
- Revenue This Year
- VVV $6.86
- TGTX $82.58
- Revenue Next Year
- VVV $14.28
- TGTX $44.99
- P/E Ratio
- VVV $18.94
- TGTX $88.20
- Revenue Growth
- VVV 7.53
- TGTX 30.96
- 52 Week Low
- VVV $31.02
- TGTX $21.16
- 52 Week High
- VVV $43.74
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- VVV 52.67
- TGTX 56.18
- Support Level
- VVV N/A
- TGTX $31.34
- Resistance Level
- VVV $40.68
- TGTX $32.56
- Average True Range (ATR)
- VVV 0.73
- TGTX 1.12
- MACD
- VVV -1.39
- TGTX 0.38
- Stochastic Oscillator
- VVV 99.89
- TGTX 72.94
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.